Netherlands Archives

News and Trends 13 Nov 2015

Curetis Molecular Diagnostics IPO Exceeds Expectations

The Southern German Med-tech for infectious disease biotech, Curetis, has sold shares up to a value of €40M, which is 10 million above its initial target, despite a lower ranged Offer price. Curetis have developed a molecular diagnostics system for hospital acquired infections (such as MRSA and Pneumonia). Their Unyvero system is a piece of […]

November 13, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Nov 2015

The 10 Hottest Bioincubators in Europe

A Bioincubator is a launch-pad structure for entrepreneurs to make their project in the sciences real. In Europe, we have many incubators within each industry, responsible for strategic investment, development and providing a support network for start-ups. Bioincubators are considered as the first ‘home’ for young biotech companies, providing entrepreneurs access to research laboratories, technology platforms, specific […]

November 10, 2015 - 5 minutesmins - By Nicolas Sainte-Foie

News and Trends 22 Oct 2015

For when it actually is Lupus: New Autoimmune Crisis Drug reaches Human Trials

ArGEN-X from Ghent (BE) and Breda (NL) has initiated its phase I human trials for Auto-immune diseases such as systemic lupus erythmatosus (SLE) – a rare chronic disease which has had little progress in the last 50 years. Here is the story behind SLE… As a rare disease, Dr. House and his fictional diagnostics team […]

October 22, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 14 Oct 2015

Curetis IPO Launched to further expand Infectious Disease Detection in Global Market

Curetis AG, the molecular diagnostics company from the Stuttgart area (Germany), has now announced its launch of an initial public offering (IPO). Previously, this biotech has raised €63.5M to develop its Unyvero Platform for testing infectious disease, including Pneumonia and biomarkers in antibiotic resistance. This new IPO aims to further commercialize this system and expand […]

October 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 5 Oct 2015

iGEM 2015: Europe still dominates World’s Largest Synthetic Biology Contest

The iGEM 2015 results are out! The World’s largest synthetic biology competition (24th – 28th September) held in Boston (US) has yet again shown up a great European representation in the winning teams. Divided into 3 tiers (Post-graduate, Under-graduate and High-School) winners and their projects are listed below. Originally launched by Massachusetts Institute for Technology […]

October 5, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)

What was AbbVie thinking? Backing out of a $1.4Bn deal to support Belgian biotech Galapagos’ rheumatoid arthritis candidate through its phase III, means NASDAQ stock is plummeting in value since Friday. With plans to work on its own phase II candidate instead, AbbVie is losing out on the potential of filgotinib, which will surely have […]

September 28, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 22 Sep 2015

UniQure’s cure for rare Lysosomal disease ready for phase III trial

UniQure from the Netherlands has promising results for its enzyme replacement therapy phase Ib/II trial targeting a rare Lysosomal disease. This has granted fast-track approval to launch its phase III trial for children with Sanfilippo Type B (MPS-III) in collaboration with France’s Institut Pasteur. UniQure is the Amsterdam gene-therapy biotech with a lot going on. Last year […]

September 22, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 17 Sep 2015

Forbion’s Dutch biotech draws Cali’s Amgen into €1.36Bn deal

Californian Amgen has announced its plans to acquire the Dutch pharma Dezima off of Forbion for €265M upfront. An additional €1.1Bn will be paid through development on their cardiovascular drug candidate which has shown good results in its phase II trial. Amgen is set to buy out Forbion’s portfolio of Amsterdam based Dezima Pharma, a […]

September 17, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

Sweden, Vegan and GMO-Free? Check out Simris Alg for your Omega-3

By running an innovative microalgae farm in Hammenhög, Sweden, Simris Alg produces a vegan and GMO-free Omega-3 fatty acid alternative to oily fish derivatives for industry. This Swedish start-up is winning all kinds of awards for their almost too-good-to-be-true approach to dietary Omega-3 oils. The Swedish entrepreneur Fredrika Gullfot (CEO) has improved upon a sustainable alternative to producing Omega-3 oils through a pioneering […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 28 Aug 2015

FDA shelves UniQure’s Glybera – will the Gene therapy once reach the US market?

The €1.1M drug Glybera was the first gene therapy on the European market. UniQure wants to sell it in the US too, but the FDA makes it much more difficult than expected. UniQure’s financial report of the first half of 2015 shows good results, cash and cash equivalents of the company increased to €181.9M, compared with […]

August 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Aug 2015

Dutch Immuno-Oncology company raises Massive Series C Financing round

Sofinnova Ventures and Novo A/S step into one of the biggest European series C financing rounds, which is about €72.8 million. The money goes to the Dutch immuno-oncology company Merus and will advance its cancer-fighting bispecific antibodies. Back in April, Merus announced its intention to go public at the Nasdaq, with the goal of raising […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Aug 2015

Dutch Startup receives €2.5M from Europe to Block Cancer’s Spreading

The Eurostars program supports the Dutch start-up Oncodrone with fresh money to bring its metastasis-blocking drug towards clinical trials. Even with a promising technology, it’s not easy to succeed in the biotech field. The Eurostars program helps small companies through the tough starting phase. This year, the 2013 founded biotech start-up Oncodrone gets a 2.5 […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us